Healthcare Analysts, along with Drs. Solomon and Appleby, discuss the upcoming Clinical Trials in Alzheimer’s Disease (CTAD) Meeting and Eisai and Biogen’s Lecanemab in the second of two Analyst/Industry conference calls to be held on December 2.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ESALY:
- Mizuho healthcare analysts to hold an analyst/industry conference call
- Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
- Biogen price target raised to $350 from $325 at Jefferies
- Biogen and Eisai’s Alzheimer’s Drug May Pose Serious Risks, Say Researchers
- Eisai and Biogen present full results for Lecanemab phase 3 study in AD